HF
SGMT icon

HRT Financial’s Sagimet Biosciences SGMT Stock Holding History

HRT Financial’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$142K Buy
+27,211
New +$152K ﹤0.01% 3281
2025
Q3 		– Sell
-69,909
Closed -$532K – 3582
2025
Q2 		$532K Buy
+69,909
New +$295K ﹤0.01% 1574
2024
Q3 		– Sell
-70,548
Closed -$241K – 3055
2024
Q2 		$241K Buy
+70,548
New +$324K ﹤0.01% 1588

Other funds holding SGMT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

HRT Financial's SGMT Position: Q1 2026 in Review

HRT Financial opened a new position in Sagimet Biosciences (SGMT) in Q1 2026: 27,211 shares worth $142K. The stake represents ﹤0.01% of the portfolio and ranks #3281 among its holdings. This is a return to the name: HRT Financial previously reported a position in SGMT as recently as Q2 2025.

HRT Financial first reported a position in SGMT in Q2 2024 and has held it in 3 quarters since. The position peaked at $532K in Q2 2025. 88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

  • HRT Financial held 27,211 shares of Sagimet Biosciences worth $142K as of Q1 2026.
  • Sagimet Biosciences was a new HRT Financial position in Q1 2026.
  • Sagimet Biosciences made up ﹤0.01% of HRT Financial's portfolio in Q1 2026, its #3281 holding.
  • HRT Financial first reported a position in Sagimet Biosciences in Q2 2024 and has held it in 3 quarters since.
  • HRT Financial's Sagimet Biosciences position peaked at $532K in Q2 2025.
  • 88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.